timeline: insulin and diabetes cell snapshot: key advances
TRANSCRIPT
Screen for candidate ALS therapeutics (Yang, 23602540)
Astroglia regulate neuronal development (Tang, 23759711)
Modeling of late-onset disease via induced aging (Miller, 24315443)
Spinal cord astrocytes (Roybon, 23994478)
Cardiomyocyte maturation (Nunes, 23793239)
Drug screening for disease-specific cardiomyo-cyte toxicity (Liang, 23519760)
Cerebral organoids model brain development and microcephaly (Lancaster, 23995685)
Pre-rosette neural stem cell culture system (Ebert, 23474892)
Drug screening and gene correction for liver disease (Choi, 23325555)
Small molecule expansion and differentiation of hepatocytes (Shan, 23728495)
Vascular endothelium (Adams, 24052946)
Endothelium with limited variation (White, 23079999)
Vascularized, functional liver from organ bud (Takebe, 23823721)
Modeling and rescue of Williams-Beuren syndrome (Kinnear, 23283491)
cGMP expansion method for neural stem cells (Shelley, 24962813)
Hyperexcitability of ALS motor neurons (Wainger, 24703839)
Automated analysis of engi-neered heart tissue (Stoehr, 24585781)
Defined chemical conditions for cardiomyocyte generation (Burridge, 24930130)
Disease modeling and drug screening for diabetic cardiomyopathy (Drawnel, 25437537)
Heart-on-chip disease modeling of Barth syndrome cardiomyopathy (Wang, 24813252)
Epicardium (Witty, 25240927)
Retinal pigment epithelium cell sheets for clinical application (Kamao, 24527394)
Self-organizing kidney (Takasato, 24335651)
3D retina with photoreceptors (Zhong, 24915161)
Gastric organoids (McCraken, 25363776)
3D kidney via redefined nephron progenitors (Taguchi, 24332837)
Lung and airway epithelium (Huang, 24291815)
Functional β cells (Pagliuca, 25303535)
Prediction of interindividual hepatocyte drug sensitivity (Takayama, 25385620)
Cord-blood endothelium (Pra-sain, 25306246)
Hutchinson-Gilford Progeria syndrome drug responses (Blondel, 24598781)
Lithium responses in bipolar disorder neurons (Mertens, 26524527)
Atrial cardiomyocyte pharmacology assesment (Devalla, 25700171)
Contractile defect from MYBPC3 mutation (Birket, 26489474)
Cardiomyocyte contractility depends on shape and substrate stiffness (Ribeiro, 26417073)
Expansion and patterning of cardiovascular progenitors (Birket, 26192318)
Hepatocyte and cardio-toxicity high content screening (Grimm, 26539751)
Cardiac drug screening system (Mathur, 25748532)
Single contracting cardiomyocytes (Feaster, 26429802)
Bioprinted 3D mini-livers (Faulkner-Jones, 26486521)
Cholangiocytes for disease modeling and drug validation (Sampaziotis, 26167629)
Cholangiocytes (Ogawa, 26167630)
3D cortical neurons and astrocytes (Paşca, 26005811)
Predicting neural toxicity (Scwartz, 26392547)
Lung organoids (Dye, 25803487)
Multi-lineage kidney organoids for modeling nephrogenesis (Takasato, 26444236)
CRISPR-mutant kidney organoids for disease modeling (Freedman, 26493500)
Nephron organoids model kidney development and injury (Moriazane, 26458176)
Cell-cell interactions enhance hepatocyte maturation (Berger, 25421237)
Influenza in IRF7 deficiency (Ciancanelli, 25814066)
Endothelial instruction of pancreas fate (Kao, 25601205)
Engineered pulmonary vascular in decellularized lungs (Ren, 26368048)
Hemogenic and arterial endothelium have distinct origins (Ditadi, 25915127)
NOTCH1 haploinsufficiency modeling (Theodoris, 25768904)
Vascularized organ bud via mesenchymal cell condensation (Takebe, 25891906)
Modeling Duchenne muscular dystrophy in muscle fibers (Chal, 26237517)
2008
NeuronalCardiacOrganoids
EndodermMesoderm: vasculature | endothelium | muscle
2009 2010
2011
2012
Amyotrophic Lateral Sclerosis (ALS) iPSCs (Dimos, 18669821)
Parkinson’s disease iPSCs (Soldner, 19269371)
Spinal muscular atrophy iPSCs (Ebert, 19098894)
Schizophrenia (Bren-nand, 21490598)
Treatment of rat model of Parkinson’s disease (Rhee, 21576821)
Transplantable astrog-lia (Krencik, 21602806 )
Optimizing cardiomyo-cyte differentiation (Kattman, 21295278)
Cardiomyocyte sur-face markers (Elliot, 22020065; Dubois, 22020386; Uosaki, 21876760)
Self-organizing 3D optic cup (Eiraku, 21475194)
Anterior foregut endo-derm (Green, 21358635)
Treatment of a rat model of arterial disease (Rufaihah, 21836062)
20132014
2015
Drug screening for ALS (Egawa, 22855461)
Probing sporadic and familial Alzheimer’s disease (Israel, 22278060)
Modeling cardiac sodium channel disease (Davis, 22647976)
Cardiovascular progenitors (Moretti, 19850773; Blin, 20335662)
Functional cardiomy-ocytes (Zhang, 19213953)
Intestinal tissue (Spence, 21151107)
Functional hepatic endoderm (Sullivan, 19877180)
Modeling liver metabolic disorder (Rashid, 20739751)
Blood-brain barrier endothelium (Lippmann, 22729031)
Vascular smooth muscle disease susceptibility (Cheung, 22252507)
Vascular and hema-topoietic cells (Leng-erke, 19796250; Taura, 19423866; Choi, 19259936)
SnapShot: Key Advances in hiPSC Disease ModelingValeria Orlova,* Christine MummeryDepartment of Anatomy and Embryology, Leiden University Medical Centre, Einthovenweg 20, 2333ZC Leiden, The Netherlands
This SnapShot presents a timeline of key advances in directed differentiation
and disease modeling using human pluripotent stem cells. The PMID for
each paper is listed after the first author’s name, and the papers are grouped
by color codes referring to different systems. A related Review by Passier et
al. (2016) in this issue of Cell Stem Cell provides further analysis of key
advances in hiPSCs over the last 10 years.
Bio-Techne™ provides an outstanding selection of high-quality reagents and assays for studying lipid metabolism, glucose homeostasis, and energy balance. For more information on innovative tools for Life Science Research, Therapeutic Manufacturing, and Clinical Diagnostics, please visit us at bio-techne.com.
Join Cell Press and Bio-Techne in celebrating the 100th anniversary of the discovery of insulin. To access a virtual panel discussion, downloadable research collections, and a PDF of this poster, visit cell.com/insulin.
2C
ell ???, ??MO
NTH
?? ??DA
TE??, 202? ©
202? Elsevier Inc.
DO
I XX
XX
XX
XX
XS
ee
online
ve
rsio
nfo
rle
ge
nds
and
refe
renc
es
SnapShot:AUTHORAFFILI ATION
An Egyptian papyrus describes symptoms compatible with diabetes
CB0551 Banting and Best extract insulin
injected to treat another dog with diabetes
Banting and Macleodare awarded the Nobel Prize for the discovery of insulin
32913291
Leonard Thompson is the first patient with diabetes treated with insulin at a Toronto hospital
2291
Timeline: 0191
Insulin deficiencyis identified as the cause of diabetes
Insulin becomes commercially availableEli Lilly startslarge-scaleproduction of insulin from cattle and pigs
Release of an extended action insulin by Novo Nordisk
6391
Release ofSulfonylureas
5591 Oral medication that stimulates insulin secretionfrom pancreas
8591
Frederick Sangeris awarded theNobel Prize for the structure of insulinInsulin becomes thefirst protein to be sequenced
9591
Classification of diabetes as “type 1” or “insulin dependent” and “type 2” or “insulinindependent”
Metformin is introduced as an antihyperglycemicagent
9591
First successful pancreas transplantationat University of MinnesotaHealth
6691
Produced by the pancreas, glucagon raises blood glucose
1691
Glucagonbecomes commercially available to treathypoglycemia
8791
Geneticallyengineeredhuman insulinGenentech clones the human insulin gene
The first synthetic human insulin is commercialized as Humulin
2891s09- s0891
Insulin pen,insulin pump,continuous glucosemonitoring
Developmentof devices to manage diabetes
0002
5002
Publication of the “Edmonton Protocol”to treat T1D withtransplanted islets
s0202
Immunotherapy for
areas of research
Future possibilities
CellMetabolism
First records of diabetes cases 3102
First SGLT2 inhibitor isapproved formedical useOral medication thatreduces glucose reabsorption from blood in thekidneys
Insulin and diabetes
1291
Centennialof insulindiscovery
1202
1925 1950 1975 2000
extracts, making clinical applicationpossible
GLP-1agonist isapproved for medicaluse
Partially restores insulin production
term glycemic control and Science, NMAH, Smithsonian Institution